Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [1] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
  • [2] Real-World Assessment of Dosing Patterns and Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia Who Initiated First-Line Single-Agent Ibrutinib in an Integrated Claims-Based Database
    Ghosh, Nilanjan
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    He, Jinghua
    Mavani, Heena
    Qureshi, Zaina
    Rogers, Kerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S329 - S330
  • [3] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Qing Huang
    Kathleen L. Deering
    Qing Harshaw
    Lori A. Leslie
    Advances in Therapy, 2022, 39 : 3292 - 3307
  • [4] Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shadman, Mazyar
    Salkar, Monika
    Srivastava, Bhavini
    Karve, Sudeep
    Emond, Bruno
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Rava, Andrew
    Sun, Haiyan
    Howarth, Amanda
    Tomicki, Samantha
    Agatep, Barnabie
    Jones, Barton
    Franceschini, Erin
    Saifan, Chadi
    Bacchus, Shaffee
    Roeker, Lindsey
    Stephens, Deborah M.
    LEUKEMIA & LYMPHOMA, 2024, : 44 - 53
  • [5] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
  • [6] Real-World Clinical Outcomes of First-Line (1L) Ibrutinib Dose Reduction Versus Acalabrutinib Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Shadman, Mazyar
    Karve, Sudeep
    Abbazio, Christopher
    Majd, Zahra
    Bacchus, Shaffee
    Saifan, Chadi
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Emond, Bruno
    Srivastava, Bhavini P.
    Stephens, Deborah M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S352 - S352
  • [7] Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia
    Hou, Jing-Zhou
    Ryan, Kellie
    Du, Senxi
    Fang, Bruno
    Marks, Stanley
    Page, Ray
    Peng, Eileen
    Szymanski, Keith
    Winters, Sharon
    Le, Hannah
    FUTURE ONCOLOGY, 2021, 17 (35) : 4959 - 4969
  • [8] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [9] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)
    Ran, Tao
    He, Jinghua
    Wu, Linda
    Panjabi, Sumeet
    Lu, Xiaoxiao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276
  • [10] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Collins, James
    Stump, Sarah E.
    Heiling, Hillary
    Muir, Michele
    Deal, Allison
    Proco, Darrian
    Nguyen, Catharine
    Cozad, Monica
    Mato, Anthony
    Coombs, Catherine C.
    Muluneh, Benyam
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1823 - 1830
12345